AMLX
HealthcareAmylyx Pharmaceuticals, Inc.
$11.39
$-0.03 (-0.26%)
Jan 5, 2026
Price History (1Y)
Analysis
Amylyx Pharmaceuticals, Inc. is a healthcare company operating in the drug manufacturers - specialty & generic industry within the broader healthcare sector. The company's market capitalization stands at $1.25B, indicating significant scale. With 123 employees, Amylyx has a moderate-sized workforce. Revenue for the trailing twelve months (TTM) is reported as -$665,000. The company's financial health is marked by low profitability and negative returns on equity and assets. Gross Margin, Operating Margin, and Profit Margin are all reported at 0.0%, indicating little to no profit from sales. Return on Equity is -56.5% and Return on Assets is -39.4%. The balance sheet shows a small amount of debt ($5.93M) against significant cash reserves ($343.99M), resulting in a Debt to Equity ratio of 1.79. Amylyx's valuation metrics are not indicative of positive growth or profitability. The Forward P/E ratio is -9.11, and the Price to Book ratio is 3.77. Revenue Growth and Earnings Growth rates for the year over year (YoY) period are listed as N/A.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. Its lead products candidate includes avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $1.25B
- P/E Ratio
- N/A
- 52-Week High
- $16.96
- 52-Week Low
- $2.60
- Avg Volume
- 1.56M
- Beta
- -0.31
Company Info
- Exchange
- NMS
- Country
- United States
- Employees
- 123